Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

Stopped early · Early Phase 1 · Has a placebo group

Conditions studied: Hemangioma, Infant

In brief

The purpose of this study is to learn about a new potential use for topical timolol 0.5% aqueous solution that may help treat small uncomplicated infantile hemangiomas. This study would examine whether topical timolol could be a potential therapy.

Key facts

Study ID

NCT01147601

Run by

Oregon Health and Science University

People needed

6

Starts

2010-03-01

Expected to finish

2014-08-01

Last updated by the study team

2017-07-05

Who can join

Age: 0 and older, up to 1. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Infants 1 month to 8 months of age with infantile hemangioma (IH) that are 3 cm or less on the scalp, trunk, or extremities.

You may not qualify if…

• Subjects with facial, genital, perianal, hand, finger, feet, or toe IH
• Subjects with PHACES (plaque-like hemangioma on the face awaiting imaging) syndrome (proven) or suspected PHACES .
• Subjects with IH measuring more than 3cm in size or ulcerated.
• Children with a history of hypersensitivity to beta blockers.
• Children with a personal history of asthma.
• Children with known renal impairment.
• Children with known cardiac conditions that may predispose to heart block
• Personal history of hypoglycemia
• Children on medications that may interact with beta blockers

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.